Home About Us

Mergers & Acquisitions

Marksans has been aggressive about its inorganic expansion policy. We are constantly working towards identifying, evaluating and acquiring key global businesses that can provide us a strategic advantage – for expanding of our product portfolio and for gaining access into key global markets.


Nova Pharmaceuticals Australasia Pty Ltd

In 2005, Marksans acquired Nova Australasia Pty Ltd. (Nova), an Australian marketing company that specializes in marketing OTC and pharmaceutical products. The company has robust operating margins and a presence across top pharmacies and major chain stores for the distribution of generics and OTC products.

The company now has 30 products in its portfolio with another 25 products awaiting TGA approvals.


Bell's Healthcare - Pharmaceuticals Manufacturer

In 2008, Marksans acquired UK's Hale Group along with its subsidiary company Bell, Sons & Co. (Druggists) Ltd. (Bell).

Bell manufactures licensed products - both as own branded products and, for certain customers, in own label form together with a range of unlicensed products. The company owns a state-of-the-art manufacturing facility in Southport and is an established manufacturer of over 200 OTC pharmaceuticals having full approval of the UK MHRA. The company currently holds 38 product licenses, which contribute towards 45% of its annual turnover.

Bell’s customers include retailers, pharmacies, chemist wholesalers and cash and carry outlets. The company enjoys a significant stronghold in the export markets. With more than 80 years of experience and a reach across 50+ countries, the brand is recognized and respected globally. Its key markets are West Africa and Middle East.


Relonchem Ltd - Generic Pharmaceutical Company

In August 2008, Marksans acquired Relonchem Ltd. The company is engaged in licensing, marketing and distribution of generic pharmaceutical products to wholesalers, retailers and hospitals in the UK.

With these successful consolidation activities, the Marksans has the potential to grow significantly due to a wider product portfolio, better market access and comprehensive R&D capacity.